In my last article about Pfizer (PFE) I discussed the upcoming loss of exclusivity (LOE) of certain brands and why I did not believe these would have a real negative effect on the stock price. But that does not mean that there are not any risk associated with an investment in this stock. I will discuss a troubling trend that could pose an increasing risk to both the company and its shareholders.
Stable top line
Pfizer has been around for quite some time. Although its financial results might fluctuate from time to time, they remain relatively stable over the long term.
